BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Oncotarget 2016;7:36767-82. [PMID: 27167344 DOI: 10.18632/oncotarget.9168] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Henriques-Pons A, Beghini DG, Silva VDS, Iwao Horita S, da Silva FAB. Pulmonary Mesenchymal Stem Cells in Mild Cases of COVID-19 Are Dedicated to Proliferation; In Severe Cases, They Control Inflammation, Make Cell Dispersion, and Tissue Regeneration. Front Immunol 2021;12:780900. [PMID: 35095855 DOI: 10.3389/fimmu.2021.780900] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Huang YH, Lian WS, Wang FS, Wang PW, Lin HY, Tsai MC, Yang YL. MiR-29a Curbs Hepatocellular Carcinoma Incidence via Targeting of HIF-1α and ANGPT2. Int J Mol Sci 2022;23:1636. [PMID: 35163556 DOI: 10.3390/ijms23031636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hosseinzadeh F, Ai J, Hajifathali A, Muhammadnejad S, Ebrahimi-Barough S, Seyhoun I, Komeili Movahed T, Shirian S, Hosseinzadeh F, Ahmadpour S, Alijani M, Verdi J. The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach. Pharmacol Rep 2022. [PMID: 35089543 DOI: 10.1007/s43440-021-00335-y] [Reference Citation Analysis]
4 Li XQ, Peng WT, Shan S, Wu JJ, Li N, Du JJ, Sun JC, Chen TT, Wei W, Sun WY. β-arrestin2 regulating β2-adrenergic receptor signaling in hepatic stellate cells contributes to hepatocellular carcinoma progression. J Cancer 2021;12:7287-99. [PMID: 35003349 DOI: 10.7150/jca.59291] [Reference Citation Analysis]
5 Moldogazieva NT, Zavadskiy SP, Sologova SS, Mokhosoev IM, Terentiev AA. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Rev Mol Diagn 2021;:1-18. [PMID: 34582293 DOI: 10.1080/14737159.2021.1987217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sakurai T, Nishida N, Kudo M. Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents. Hepatobiliary Surg Nutr 2020;9:777-9. [PMID: 33299833 DOI: 10.21037/hbsn.2020.03.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wu L, Zhou J, Zhou W, Huang XF, Chen Q, Wang W, Zhai L, Li S, Tang Z. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo. Pathol Res Pract 2021;220:153270. [PMID: 33640712 DOI: 10.1016/j.prp.2020.153270] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Gao S, Ni Q, Wu X, Cao T. GHR knockdown enhances the sensitivity of HCC cells to sorafenib. Aging (Albany NY) 2020;12:18127-36. [PMID: 32970612 DOI: 10.18632/aging.103625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
9 Jing Z, Ye X, Ma X, Hu X, Yang W, Shi J, Chen G, Gong L. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Cancer Med 2020;9:4324-38. [PMID: 32324343 DOI: 10.1002/cam4.3020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
10 Liu L, Chen J, Cao M, Wang J, Wang S. NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 2019;84:1303-14. [PMID: 31555866 DOI: 10.1007/s00280-019-03965-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Liu Y, Li H, Dong J, Ma L, Liao A, Rong Z, Zhou Z, Cao L, Wang F, Wang J, Wang A. mTOR and ERK regulate VKORC1 expression in both hepatoma cells and hepatocytes which influence blood coagulation. Clin Exp Med 2019;19:121-32. [PMID: 30306378 DOI: 10.1007/s10238-018-0528-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Dai N, Ye R, He Q, Guo P, Chen H, Zhang Q. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling. Oncol Rep 2018;40:3235-48. [PMID: 30272354 DOI: 10.3892/or.2018.6754] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
13 Bao Y, Yang F, Liu B, Zhao T, Xu Z, Xiong Y, Sun S, Qu L, Wang L. Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response. Br J Cancer 2018;119:450-61. [PMID: 30033448 DOI: 10.1038/s41416-018-0189-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chen Y, Wang X, Cao C, Wang X, Liang S, Peng C, Fu L, He G. Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells. Oncotarget 2017;8:104193-205. [PMID: 29262632 DOI: 10.18632/oncotarget.22119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
15 Xu Q, Liu X, Liu Z, Zhou Z, Wang Y, Tu J, Li L, Bao H, Yang L, Tu K. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway. Mol Cancer 2017;16:103. [PMID: 28606154 DOI: 10.1186/s12943-017-0675-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 102] [Article Influence: 14.8] [Reference Citation Analysis]
16 Zhang H, Wang Y, Liu Z, Yao B, Dou C, Xu M, Li Q, Jia Y, Wu S, Tu K, Liu Q. Lymphocyte-specific protein 1 inhibits the growth of hepatocellular carcinoma by suppressing ERK1/2 phosphorylation. FEBS Open Bio 2016;6:1227-37. [PMID: 28255535 DOI: 10.1002/2211-5463.12139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
17 Cui SX, Yu XF, Qu XJ. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma. Cancer Invest 2016;34:459-64. [PMID: 27673353 DOI: 10.1080/07357907.2016.1227445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
18 Wu Y, Zhou D, Xu X, Zhao X, Huang P, Zhou X, Song W, Guo H, Wang W, Zheng S. Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma. World J Surg Oncol 2016;14:179. [PMID: 27389277 DOI: 10.1186/s12957-016-0922-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]